Real estate investment and management company with residential properties in Massachusetts and New York.

• Successfully established sponsored research agreements with four leading research institutions for access to patient samples for whole genome sequencing with access to longitudinal clinical profiles (with Dr. Phillip Reilly, Third Rock)• Assembled team to sequence over 2350 patients with focal segmental glomerular sclerosis/idiopathic progressive proteinuria and acquire over 3800 ancestry-matched controls. Currently adding 500 diabetic kidney disease patients and 500 diabetic controls. • Developed strategy for biochemical validation of potential pathogenic variants to inform target identification and clinical trial enrollment. Currently directing CROs to validate more than 100 novel variants as drivers of pathway dysregulation leading to proteinuria kidney disease, including generation of iPSCs from patient samples and CRISPR gene editing for testing compounds in our kidney organoid platform. • Led team to evaluate options and deploy research computational infrastructure including compound registry, ELN, results management, SAR tools, computational chemistry, NGS pipeline, and multi-omics data warehouse on AWS. Currently building phenotype-genotype patient database with dashboards. • Oversaw all research informatics and general IT infrastructure projects, now managed by my Director of IT/Informatics. Additional direct reports are statistical geneticist, computational biologist, computational chemist and translational informatics developer. • Advisor to medicinal chemistry team, including HTS, virtual screening, analog design, modeling ligand shape and protein-ligand interactions (co-inventor on patent filings).

• Worked with founding members and partners at Third Rock Ventures (Neil Exter and Abbie Celniker) to refine the company concept and prepare for Series A funding and launch of Goldfinch Bio

Analysis and interpretation of next-gen sequencing, expression profiling, copy-number variant, and proteomics data in support of multiple drug discovery and development programs. Analysis of IHC and RNAScope images for biomarker quantification in molecular pathology. Molecular modeling, computational chemistry and management of x-ray crystallography for medicinal chemistry.

Cheminformatics: Early discovery research on several new targets in oncology, inflammation and pain, working closely with chemists, biochemists and cell biologists. Target proposal with initial literature search and due diligence. Identification and investigation of new chemical matter against these targets which is well suited for optimization by medicinal chemistry. Leader of computational chemistry effort including protein homology modeling with covalent and non-covalent docking of ligands using GOLD, Schrödinger, and MOE. Design of new analogs and recommendations for synthesis.Bioinformatics: Involved in managing, planning and prioritizing Bioinformatics studies and coordinating these efforts with Molecular Pathology. Transcriptional profiling, Sanger sequencing, next-gen sequencing and proteomics technologies are being used for drug target identification and to identify biomarkers for predicting chemical sensitivity/tox, PD, and patient stratification. Cell Line Inventory/Mutation Database. 1 direct report in Computational Biology.Pathology Informatics: Working on Molecular Pathology infrastructure projects with integration of laboratory instrumentation and workflow. Evaluation and recommendation of software tools for histological and immunofluorescence image analysis. Augmentation of Aperio, TissueGnostics and TissueStudio algorithms with Definiens Developer and custom analysis pipelines using Python, Perl, ImageJ, and leveraging open-source.

Contributor to multiple drug discovery project teams providing structural biology, protein-ligand docking, analog design and computational chemistry expertise. Primarily focus is on early discovery projects in oncology from inception to candidate selection. Involved in evaluation and due diligence of potential new discovery projects. Manager of external structural biology collaborations (x-ray, NMR) and supervisor of in-house modeling/computational chemistry effort.

Provided computational chemistry and structural biology support for several drug discovery projects, working closely with medicinal chemists to formulate binding models and leverage crystal structures in analog design. Developed virtual co-crystal database and web-based client using .NET and web services.

Manager and technical contributor to target validation, design of specific inhibitors, translation of design into practice, in-vitro testing, early preclinical studies, and identification, management and protection of intellectual property. Managed 3-5 CROs, 1 direct report.

Installed and configured a chemical database for compound registration and tracking. Added custom extensions to integrate biochemical and cellular assay data. Developed an image analysis program to estimate the concentration and subcellular localization of target proteins in cancer cell lines and tumor sections, based on immunohistological staining.

Developed a custom web-based software application to automate nonlinear curve fitting (with handling of outliers) for efficient estimation and storage of kinetic parameters from biochemical assays. Further extended the compound database infrastructure to integrate antibacterial assay data.

Manager and/or technical leader on software projects involving computer imaging, embedded processors, systems integration and Internet strategy. Fortune 500 clients included Teradyne, HP, and Polaroid.

Manager of small teams of engineers developing customized software applications for customers under strict deadlines. Developed software applications for real-time embedded control systems and robotics to improve efficiency and throughput of laser memory repair systems. Fortune 500 clients included Analog Devices, Maxim and Dominion Semiconductor. Managed 3 direct reports.